{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-292015","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.791055+00:00","generated_at":"2026-05-16T17:21:57.094878+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa Pharma enters into $250M ATM equity offering facility with Leerink Partners","bullets":["Up to $250M of American Depositary Shares may be sold through Leerink as sales agent.","Commission of 3.0% on gross proceeds; Leerink also receives up to $150K legal expense reimbursement.","No minimum offering amount; net proceeds expected for working capital, capex, and general corporate purposes.","Amends and restates prior sales agreement dated January 27, 2023, with Leerink."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-292015","json":"https://secwatch.observer/filing/0001193125-25-292015.json","markdown":"https://secwatch.observer/filing/0001193125-25-292015.md","text":"https://secwatch.observer/filing/0001193125-25-292015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525292015/0001193125-25-292015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525292015/d23843d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:21:57.094878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}